Handelsbanken Fonder AB Acquires New Stake in Mirum Pharmaceuticals, Inc. $MIRM

Handelsbanken Fonder AB acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 213,500 shares of the company’s stock, valued at approximately $16,864,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MCF Advisors LLC grew its position in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Quarry LP acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at $41,000. CWM LLC lifted its holdings in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the period. Finally, Comerica Bank lifted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 4,732 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $435,249.36. Following the completion of the transaction, the senior vice president owned 8,429 shares of the company’s stock, valued at $775,299.42. The trade was a 35.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Peter Radovich sold 16,515 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $1,519,049.70. Following the transaction, the chief operating officer directly owned 40,272 shares of the company’s stock, valued at $3,704,218.56. This trade represents a 29.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 76,806 shares of company stock worth $7,064,616. Insiders own 14.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MIRM shares. Wolfe Research started coverage on Mirum Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $145.00 target price for the company. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Stifel Nicolaus set a $136.00 target price on Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $132.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $137.08.

Mirum Pharmaceuticals Trading Up 1.4%

NASDAQ:MIRM opened at $96.95 on Thursday. The company has a market capitalization of $5.91 billion, a PE ratio of -7.12 and a beta of 0.52. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 52-week low of $42.89 and a 52-week high of $114.99. The stock has a fifty day simple moving average of $95.87 and a 200-day simple moving average of $88.14.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The firm had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.30) EPS. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.